Evidence map›Paper›PMID 38050021›Full record

ArticleCold Spring Harbor molecular case studies2023

Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.

Kyle M Hernandez, Aarti Venkat, Danne C Elbers, John R Bihn, Mary T Brophy, Nhan V Do, Jennifer La, Qiong Liu, Andrew Prokhorenkov, Noah Metoki-Shlubsky and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Kyle M Hernandez *Belay Diagnostics, Chicago, Illinois 60607, USA.ORCID 0000-0001-8267-644X
Aarti Venkat *Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA.ORCID 0000-0002-4744-8211
Danne C Elbers *VA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts 02130, USA.ORCID 0000-0002-0454-0173
John R BihnVA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts 02130, USA.ORCID 0000-0001-8029-8991
Mary T BrophyVA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts 02130, USA.ORCID 0000-0003-2314-4368
Nhan V DoVA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts 02130, USA.ORCID 0000-0001-6868-7011
Jennifer LaVA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts 02130, USA.ORCID 0000-0003-2266-0221
Qiong LiuFrederick National laboratory for Cancer Research, Frederick, Maryland 21701, USA.ORCID 0009-0008-2042-4480
Andrew ProkhorenkovCenter for Translational Data Science, University of Chicago, Chicago, Illinois 60637, USA.ORCID 0000-0002-9460-9719
Noah Metoki-ShlubskyCenter for Translational Data Science, University of Chicago, Chicago, Illinois 60637, USA.
Feng-Chi SungVA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts 02130, USA.
Channing J Paller *The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA; cpaller1@jhmi.edu nathanael.fillmore@va.gov rgrossman1@uchicago.edu.ORCID 0000-0003-3658-1858
Nathanael R Fillmore *VA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts 02130, USA; cpaller1@jhmi.edu nathanael.fillmore@va.gov rgrossman1@uchicago.edu.ORCID 0000-0002-8058-3423
Robert L Grossman *Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA.ORCID 0000-0003-3741-5739
University of Chicago · USBoston University · USHarvard University · USVA Boston Healthcare System · USJohns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

Veterans are at an increased risk for prostate cancer, a disease with extraordinary clinical and molecular heterogeneity, compared with the general population. However, little is known about the underlying molecular heterogeneity within the veteran population and its impact on patient management and treatment. Using clinical and targeted tumor sequencing data from the National Veterans Affairs health system, we conducted a retrospective cohort study on 45 patients with advanced prostate cancer in the Veterans Precision Oncology Data Commons (VPODC), most of whom were metastatic castration-resistant. We characterized the mutational burden in this cohort and conducted unsupervised clustering analysis to stratify patients by molecular alterations. Veterans with prostate cancer exhibited a mutational landscape broadly similar to prior studies, including

Indexed as

Prostatic NeoplasmsVeteransHumansMaleMedical OncologyMutationPrecision MedicineRetrospective Studiesneoplasia of the male external genitalia

Identifiers

PMID38050021
PMCPMC10815278
OpenAlexW4388899121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.